InsiderSignal.AI

InsiderSignal.ai

KNSA - Kiniksa Pharmaceuticals International, Plc

Insider Sale by Quart Barry D (Dir)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

3 days ago, Quart Barry D, serving as Dir at Kiniksa Pharmaceuticals International, Plc (KNSA), sold 6,901 shares at $50.00 per share, for a total transaction value of $345,050.00. Following this transaction, Quart Barry D now holds 12,546 shares of KNSA.

This sale represents a 35.00% decrease in Quart Barry D's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, April 6, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, April 8, 2026, 2 days after the trade was made.

Kiniksa Pharmaceuticals International, Plc operates in the HEALTHCARE sector, specifically within the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Quart Barry D

Dir

Barry D. Quart, Pharm.D., age 68, is an independent Director at Kiniksa Pharmaceuticals International, plc (KNSA) since 2015, serving on the Audit, Compensation, and Science & Research Committees.[[1]](https://fintool.com/app/research/companies/KNSA/people/barry-d-quart)[[2]](https://www.marketscreener.com/insider/BARRY-QUART-A01UEG/) He recently traded shares in the company, with his last reported transaction on June 11, 2025.[[4]](https://insiderinsights.com/savvy-analysis/quart-barry-d/1384243?i=1730430)[[6]](https://longbridge.com/en/news/270065504) Dr. Quart holds a Pharm.D. from the University of California, San Francisco, and brings over 30 years of biotechnology leadership, including co-founding Ardea Biosciences (President/CEO until its 2013 sale to AstraZeneca), where he oversaw development of ZURAMPIC®, and serving as CEO of Heron Therapeutics (2013–2023), leading FDA approvals of four drugs: CINVANTI®, SUSTOL®, ZYNRELEF®, and APONVIE®.[[1]](https://fintool.com/app/research/companies/KNSA/people/barry-d-quart)[[2]](https://www.marketscreener.com/insider/BARRY-QUART-A01UEG/)[[3]](https://www.citybiz.co/article/697435/qa-with-barry-quart-ceo-at-connect-biopharma/) Currently, he is CEO of Connect Biopharma Holdings Ltd. (since June 2024) and Director at NeuroGenetic Pharmaceuticals, Inc.[[1]](https://fintool.com/app/research/companies/KNSA/people/barry-d-quart)[[2]](https://www.marketscreener.com/insider/BARRY-QUART-A01UEG/) He previously led Pfizer’s La Jolla R&D site and Agouron/Warner-Lambert, with 18 U.S. patents and 75 publications.[[1]](https://fintool.com/app/research/companies/KNSA/people/barry-d-quart)[[3]](https://www.citybiz.co/article/697435/qa-with-barry-quart-ceo-at-connect-biopharma/)

View full insider profile →

Trade Price

$50.00

Quantity

6,901

Total Value

$345,050.00

Shares Owned

12,546

Trade Date

Monday, April 6, 2026

3 days ago

SEC Filing Date

Wednesday, April 8, 2026

Filed 2 days after trade

HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC

About Kiniksa Pharmaceuticals International, Plc

Company Overview

No company information available
View news mentioning KNSA

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5473351

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime